|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/00 | |
| A61K 39/00 | |||
| C07K 16/46 | |||
| C07K 14/705 | |||
| A61K 39/395 |
| (11) | Patento numeris | 2875046 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 13742802.5 |
| Europos patento paraiškos padavimo data | 2013-07-18 | |
| (97) | Europos patento paraiškos paskelbimo data | 2015-05-27 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-02-26 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2013/051097 |
| Data | 2013-07-18 |
| (87) | Numeris | WO 2014/015148 |
| Data | 2014-01-23 |
| (30) | Numeris | Data | Šalis |
| 201261673639 P | 2012-07-19 | US |
| (72) |
ARNETT, Heather A., US
ESCOBAR, Sabine S., US
SWANSON, Ryan M., US
VINEY, Joanne L., US
|
| (73) |
Amgen Inc.,
One Amgen Center Drive, Thousand Oaks, California 91320-1799,
US
|
| (54) | HUMAN BTNL3 PROTEINS, NUCLEIC ACIDS, AND ANTIBODIES AND USES THEREOF |
| HUMAN BTNL3 PROTEINS, NUCLEIC ACIDS, AND ANTIBODIES AND USES THEREOF |